CYP4F2 and metabolic dysfunction-associated steatohepatitis: CYP4F2 gene polymorphisms affects vitamin E to improve the liver of nonalcoholic fatty liver disease children and adults who participated in the Treatment of Nonalcoholic Fatty Liver Disease in Children and Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis Histology, but there are obvious individual differences in its efficacy [17].